A New Approach to Produce HIV-1 Envelope Trimmers

**BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS**

Received for publication, April 3, 2015, and in revised form, June 17, 2015. Published, JBC Papers in Press, June 18, 2015, DOI 10.1074/jbc.M115.656611

Wadad AlSalmi, Marthandan Mahalingam, Neeti Ananthaswamy, Christopher Hamlin, Dalia Flores, Guofen Gao, and Venigalla B. Rao

From the Department of Biology, The Catholic University of America, Washington, D. C. 20064

**Background:** HIV-1 envelope trimer is a candidate for designing an effective HIV vaccine.

**Results:** gp140 attached to Strep-tag through a long linker is used to purify HIV trimers. Cleaved, uncleaved, and fully and partially glycosylated trimers are characterized.

**Conclusion:** Cleaved and glycosylated gp140 assembles into authentic propeller-shaped trimers.

**Significance:** This system could generate HIV-1 trimers for clinical trials and vaccine manufacture.

The trimeric envelope spike of HIV-1 mediates virus entry into human cells. The exposed part of the trimer, gp140, consists of two noncovalently associated subunits, gp120 and gp41 ectodomain. A recombinant vaccine that mimics the native trimer might elicit entry-blocking antibodies and prevent virus infection. However, preparation of authentic HIV-1 trimers has been challenging. Recently, an affinity column containing the broadly neutralizing antibody 2G12 has been used to capture recombinant gp140 and prepare trimers from clade A BG505 that naturally produces stable trimers. However, this antibody-based approach may not be as effective for the diverse HIV-1 strains with different epitope signatures. Here, we report a new and simple approach to produce HIV-1 envelope trimers. The C terminus of gp140 was attached to Strep-tag II with a long linker separating the tag from the massive trimer base and glycan shield. This allowed capture of nearly homogeneous gp140 directly from the culture medium. Cleaved, uncleaved, and fully or partially glycosylated trimers from different clade viruses were produced. Extensive biochemical characterizations showed that cleavage of gp140 was not essential for trimerization, but it triggered a conformational change that channels trimers into correct glycosylation pathways, generating compact three-blade propeller-shaped trimers. uncleaved trimers entered aberrant pathways, resulting in hyperglycosylation, nonspecific cross-linking, and conformational heterogeneity. Even the cleaved trimers showed microheterogeneity in gp41 glycosylation. These studies established a broadly applicable HIV-1 trimer production system as well as generating new insights into their assembly and maturation that collectively bear on the HIV-1 vaccine design.

AIDS, caused by HIV-1, is a global epidemic. More than 30 million people worldwide currently live with HIV infection, and nearly 2 million people die of AIDS every year. Nine genetic subtypes and numerous circulating recombinant forms have been identified. Coupled with this diversity is the extraordinary evolution of the viral envelope protein (Env) in response to host immune pressures. Designing an Env immunogen that can stimulate antibodies (Abs), which in turn can block entry of genetically diverse HIV-1 viruses, has remained as the “holy grail” of the HIV vaccine field (1, 2).

The trimeric Env spike of the HIV-1 virion is the virus entry machine. It is a trimer of heterodimers composed of the glycoproteins gp120 and gp41 produced by cleavage of the precursor protein gp160 (3, 4). Entry involves a series of well orchestrated interactions between these proteins and the receptor molecules present on the target cell (5). The first step might be the capture of the virus through interactions between the V1V2 domain of gp120 and a surface molecule, such as the α4β7 integrin of the mucosal T lymphocytes (6, 7). This might bring the virus into close proximity to CD4, the primary receptor. Binding to CD4 causes a conformational change in gp120, exposing a site in the V3 domain that binds to the chemokine co-receptor CCR5 or CXCR4 (8–13). A series of conformational changes ensue, resulting in the insertion of the gp41 fusion peptide into the host cell membrane (14). The viral lipid bilayer fuses with the plasma membrane, releasing the nucleocapsid core into the target cell (15). Therefore, Env-specific Abs that can interfere with any of the steps common to diverse HIV-1 viruses can prevent transmission of HIV into the host.

Several human monoclonal Abs (mAbs), referred to as broadly neutralizing Abs (BnAbs), have been discovered that can neutralize infection of a large spectrum of genetically diverse HIV-1 viruses. These include, for instance, BnAbs b12 and VRC01, which bind to the CD4 binding site of gp120; 2F5 and 4E10, which bind to the membrane-proximal external region (MPER) of gp41; and PG9 and PG16, which bind to the membrane-proximal external region (MPER) of gp41; and PG9 and PG16, which bind to the
Production and Characterization of HIV-1 Envelope Trimers

V1V2 domains of the trimer (16–19). Most of these Abs recognize conformational epitopes and are produced either by “elite controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).

One reason for this failure may be that the subunit Env immunogens do not recapitulate the trimeric structure of the native Env spike present on the HIV-1 virion (26). It has been hypothesized that exposure to “native” trimers could lead to activation and expansion of rare B cell clones of the right BnAb “controller” individuals with chronic HIV infections or by selection of rare B cell clones present in HIV-1-infected individuals (20). They also exhibit unusual features, such as the presence of a long heavy chain 3 complementarity-determining region covering a large area of the epitope as well as dozens of somatic mutations introduced by a process known as “affinity maturation” driven by the evolving envelope protein (21). Attempts to induce such BnAbs in animal models or in humans by vaccination with recombinant Env immunogens have thus far failed (22–25).
The gp140 (and gp120) clones were constructed by either overlap extension PCR (56) or gene assembly PCR (57) using appropriate sets of primers. Restriction sites for Nhel and NotI were introduced into the end primers. The amplified DNAs were digested with Nhel and NotI and purified by agarose gel electrophoresis. The DNAs were then ligated with the Nhel-NotI-digested and dephosphorylated pCDNA3.1 (−) plasmid DNA. Directional insertion of gp140 DNA resulted in the in-frame fusion of gp140 with CD5 signal peptide at the N terminus and the alanine linker followed by various tags at the C terminus (see "Results"). The gp140 (and gp120) clones were transformed into 5-α competent E. coli cells (New England BioLabs, Inc.), and the plasmid DNAs were purified using the GeneJET plasmid miniprep kit (Life Technologies). The DNAs were then sequenced to confirm 100% accuracy of the cloned gp140 DNA. For transfection into mammalian cells, the plasmid DNAs were purified using the GeneJET Plasmid Midiprep kit (Life Technologies) as per the manufacturer's instructions.

**Small Scale Transfection**—Suspension cells HEK293F (Life Technologies) and HEK293S GnT I (ATCC CRL-3022) were maintained in FreeStyle 293 expression medium (Life Technologies). The cells were incubated in a Multitron Pro shaker (Infors HT) at 37 °C in 8% CO₂. In the case of HEK293S GnT I, the growth medium was supplemented with 1% heat-inactivated fetal bovine serum (FBS, Quality Biologicals). For transfection, cells were grown overnight to a density of 1 × 10⁶ cells/ml. Two h prior to transfection, 6-ml cultures were centrifuged at 100 × g for 5 min and resuspended in fresh medium to a density of 2 × 10⁶ cells/ml in the absence of FBS. Three ml of cells were then transfected to each well of a 16.8-ml 6-well Clear plate (Corning Inc.). For cleavage resistant (CR) cells were then transferred to each well of a 16.8-ml 6-well Clear plate (Corning). For cleavage-proficient (CP) DNA, the cells were co-transfected using the GeneJET Plasmid Midiprep kit (Life Technologies) as per the manufacturer's instructions.

**Large Scale Transfection**—Transfection was carried out in a manner similar to the small scale transfection, but it was scaled up to 1.2-liter cultures in a 2.8-liter flask and incubated at 37 °C in 8% CO₂ while shaking at 90 rpm overnight. After 12 h, 2 ml of fresh medium, 1 ml of HyClone SFM4HEK293 medium (GE Healthcare), and protein expression-enhancing sodium butyrate (58) solution (Sigma-Aldrich) to a final concentration of 2 μM were added to the cells. On day 5, the supernatant was harvested and clarified using a 0.2-μm filter (Corning).

**Large Scale gp140 Purification**—To inactivate biotin present in the supernatant, 20 μl of Bio-Lock biotin blocking solution (IBA Life Sciences) was added to 5 ml of the supernatant containing the secreted gp140 (or gp120). After a 30-min incubation at 4 °C, 100 μl of Strep-Tactin beads (Qiagen) were added and allowed to rotate overnight at 4 °C. The bead mixture was spun down at 200 rpm to pellet the beads. The beads were then applied to a spin column (Pierce), briefly centrifuged to remove residual supernatant, and then washed twice with 50 mM Tris-HCl, pH 8, and 300 mM NaCl. The bound gp140 or gp120 proteins were eluted with 200 μl of Strep-Tactin elution buffer (2.5 mM d-desthiobiotin (Sigma), 25 mM Tris-HCl, pH 8, and 150 mM NaCl).

**Large Scale gp140 Purification**—To prevent nonspecific protease degradation, protease inhibitor tablets (Roche Diagnostics) were added to the clarified supernatant according to the manufacturer's instructions. To inactivate free biotin present in the culture medium, BioLock-biotin blocking solution (IBA Life Sciences) was added, and the medium was incubated at 4 °C for 30 min. The gp140 was purified by Strep-Tactin affinity chromatography followed by size exclusion chromatography (SEC). The supernatants were loaded onto a 1-ml Strep-Tactin column (Qiagen) at 0.7 ml/min using the ÄKTA Prime-Plus liquid chromatography system (GE Healthcare). Nonspecifically bound proteins were washed off by passing at least 20 column volumes of wash buffer (50 mM Tris-HCl, pH 8, and 300 mM NaCl) until the absorbance reached the baseline level. The Strep-tagged gp140 proteins were then eluted with elution buffer (2.5 mM d-desthiobiotin (Sigma), 25 mM Tris-HCl, pH 8, and 150 mM NaCl) at a flow rate of 1 ml/min. The peak fractions were pooled and concentrated using 100,000 molecular weight cut-off Amicon Ultra-4 centrifugal filter units (Millipore). The samples were then applied to a Hi-Load 16/600 Superdex-200 (preparation grade) size exclusion column (GE Healthcare) equilibrated with the gel filtration buffer (25 mM Tris-HCl, pH 8, 150 mM NaCl). Chromatography was done using the ÄKTA FPLC system (GE Healthcare), and fractions were collected and stored in 10% glycerol at −80 °C.

The gp140 clones fused to hexahistidine or octahistidine tags were purified by HisTrap affinity chromatography followed by SEC. The culture supernatant was loaded onto a 1-ml HisTrap HP column (GE Healthcare) at a flow rate of 0.7 ml/min using the ÄKTA Prime-Plus liquid chromatography system (GE Healthcare). Nonspecifically bound proteins were removed using a buffer containing 50 mM Tris-HCl, pH 8, 300 mM NaCl, and 20 mM imidazole until the absorbance reached the baseline level. The proteins were then eluted using a 20–500 mM imidazole gradient. The peak fractions were then applied to a Hi-Load 16/600 Superdex-200 (preparation grade) size exclusion column (GE Healthcare) and purified as described above.

**SDS-PAGE and Blue Native PAGE (BN-PAGE)**—SDS-PAGE analyses were performed using 4–20% gradient Tris-glycine gels (Life Technologies) or homemade 10% gels in the presence (reducing) or absence (non-reducing) of DTT. The BlueStain protein ladder 11–245 kDa (Gold Biotechnology) was used as a molecular mass marker. BN-PAGE was performed using the Novex NativePAGE BisTris gel system in 4–16% gradient gels according to the manufacturer’s instructions (Life Technologies). In the case of JRFL-FD, a native 4–12% gradient Tris-glycine gel (Life Technologies) was used with Tris-glycine buffer (Bio-Rad). The NativeMark unstained protein standard buffer containing 50 mM Tris-HCl, pH 8, 300 mM NaCl, and 20 mM imidazole until the absorbance reached the baseline level. All gels were stained with Coomassie Blue R-250 solution.

**Protease Cleavage**—SEC-purified gp140 trimers were incubated with 10-fold serial dilutions (1–0.01 μg/ml) of Proteinase K (Thermo Scientific) at 37 °C for 1 h. The same preparation incubated at 37 °C without protease was used as a negative control. The samples were electrophoresed on
reducing SDS gels for CR gp140 and non-reducing SDS gels for CP gp140.

Deglycosylation—For Strep-Tactin-purified gp140, 1 μl (500 units) of PNGase F (New England BioLabs, Inc.) was used to deglycosylate 10 μg of protein in the absence of DTT following the manufacturer’s instructions. For SEC-purified trimers, deglycosylation was performed under native conditions using 3 μl (1,500 units) of PNGase F per 10 μg of protein and by incubating for 5 h at room temperature.

Strept-Tactin ELISA—Strep-Tactin-coated microplates (IBA Life Sciences) were coated with 1 μg/ml SEC-purified gp140 trimers in a volume of 100 μl/well of buffer (25 mM Tris-HCl, pH 7.6, 2 mM EDTA, and 140 mM NaCl) and incubated for 2 h at room temperature. Following three washes with PBST (0.05% Tween 20 in PBS), 100 μl of serially diluted Abs (10–0.001 μg/ml) in PBS were added to the wells, and the plates were incubated for 1 h at 37 °C. After three washes with PBST, the plates were incubated with 100 μl of rabbit anti-human Ab HRP conjugate (Santa Cruz Biotechnology) diluted 1:3,000 in PBS for 30 min at 37 °C. The plates were then washed three times with PBST, and the peroxidase substrate was added to develop the color reaction (TMB microwell peroxidase substrate system and Image Lab software).

Western Blotting—Polyclonal mouse Abs against HIV-1 JRFL gp140 were used as the primary Ab, and rabbit HRP-conjugated anti-mouse IgG (H+L) was used as the secondary Ab (Novex, Life Technologies). For Strep-tag II detection, StrepMAB-Classis HRP-conjugated Ab (IBA Life Sciences; dilution 1:1,000 in PBS) was used. Band intensities were measured using the Bio-Rad Gel Doc XR+ system and Image Lab software.

Negative Stain EM—Samples were diluted to 20–30 μg/ml and added to a glow-discharged carbon-coated grid. Samples were left on the grid for 2 min, blotted with a filter paper, and stained with Nano-W (Nanoprobes, Yaphank, NY) for 30 s, with two cycles of rinsing followed by stain application. After the last round of staining, the grid was blotted and allowed to dry completely before being imaged. Grids were imaged on an FEI Tecnai T12 microscope operating at 120 kV. Images were captured at a nominal magnification of ×67,000 on a Gatan UltraScan CCD using a dose of 20 electrons/Å². Particles were selected semiautomatically using e2boxer within EMAN2 with a box width of 200 Å. Reference-free two-dimensional class averages were generated using EMAN2 (59). Briefly, several particles were manually picked to initiate automated particle picking using e2boxer within EMAN2. After automated particle picking, reference-free two-dimensional class averages were generated using e2refine2d within EMAN2. Each sample went through 15 iterations of two-dimensional classification, and 32 classes were generated per sample.

Results

Conventional Strategies Have Not Been Very Effective at Producing HIV-1 Env Trimers—We have tested several codon-optimized gp140 constructs from HIV-1 strains JRFL, SF162 (clade B viruses), and CONPEP (clade C) for production of Env trimers. The gp140 DNA containing gp120 and gp41 ectodomain sequences truncated at aa 664 or 683 (HXB2 numbering) was cloned under the control of the CMV promoter (Fig. 1A) and transfected into a variety of mammalian cell lines (293F, 293T, 293EXPI, CHO, and GnTI−). With a signal peptide fused to the N terminus, gp140 was secreted into the culture medium, and the efficiency of production was quantified. Both CR and CP clones were tested. For CR gp140, the furin cleavage site REKR between gp120 and gp41 was mutated to SEKS, and for CP gp140, it was mutated to RRERRR and co-transfected with a second furin-containing plasmid to enhance cleavage (53). Of the three signal peptides tested, CD5, tissue plasminogen activator, and Gaussia Luciferase, CD5 showed consistently better expression. Fusing a hexahistidine (His) tag at the C terminus of gp140 did not affect expression, whereas an N-terminal tag showed poor expression probably because the hydrophilic tag affected cleavage of the adjacent, largely hydrophobic,
signal peptide. However, the C-terminal tag bound poorly, if at all, to nickel-agarose.

Clones were also constructed by inserting the 27-aa phage T4 fibritin trimerization motif (foldon, or FD) (49) between the C terminus of gp140 and the His tag (e.g. JRFL; Fig. 1A). These produced a mixture of trimers and higher oligomers but no protomers (monomers or dimers). These, however, bound to nickel-agarose and could be further purified by SEC, which resolved the oligomers, but the elution profiles overlapped (Fig. 1, B–D). These results are consistent with the foldon-based trimers reported by other investigators (26, 60, 61) (also see Table 1). Further, our biochemical analyses showed that the protomers of these trimers are nonspecifically cross-linked with disulfide bonds (see below).

We also constructed recombinants without any tag and captured gp140 using lectin beads (Galanthus nivalis lectin or concanavalin A). The protein was then purified by SEC. However, the yields of the trimers varied either by direct application of the culture supernatant or after 2–3× concentration by tangential flow filtration. We also encountered aggregation of some of the gp140 during lectin chromatography, and furthermore, the binding potency of lectin diminished progressively after each use.

### Table 1

| Ligand | gp140 | Specificity | Elution | Purity | End specificity | Quality of trimers | Stripping | Re-use | Capacity | Cost |
|--------|-------|-------------|---------|--------|----------------|-------------------|-----------|--------|----------|------|
| Galanthus nivalis lectin attached to solid matrix | Wild-type | Low, broad | Strong reagent (1 M mannose) | No | Medium | The co-purified contaminants might affect the quality of the trimers | Not reported | Limited | Low to Medium | $130 for 2 ml or 6 mg of Galanthus nivalis lectin GNL (Vector Laboratories) |
| BnAb 2G12 coupled to Sepharose 4B (28) | Wild-type | High, narrow | Strong reagent (3 M MgCl2) | No | Medium | Captures only the envelope protein molecules containing the 2G12 epitope; these include gp120, gp140 protomers (monomers and dimers) and trimers | Not reported | Not reported | Low to Medium | $565 for 1 mg of 2G12 Ab (Polymun Scientific) |
| Ni (or a heavy metal such as Co) attached to solid matrix | The 27-aminoo acid trimerization motif, referred to as foldon or fibritin, followed by His-tag fused to the C-terminus of gp140 | High | Strong reagent (200–400 mM imidazole) | Yes | High | In addition to His-tag containing gp140 protomers (monomers and dimers) and trimers, Ni can nonspecifically bind to non-target contaminating proteins | Yes | High | Low to Medium | $23 for 2 ml of Ni-NTA Agarose (Qiagen) |
| Modified streptavidin, referred to as Strep-Tactin, attached to solid matrix | The 8-aminoo acid Strep-Tag II peptide with a 27-aminoo acid linker fused to the C-terminus of gp140 | High | Mild reagent (2.5 mM d-Desthiobiotin) | Yes | High | Because of high specificity to Strep-Tactin, only the Strep-Tag containing gp140 protomers (monomers and dimers) and trimers will be captured | Yes | High | High | $166 for 2 ml of Strep-Tactin Superflow Plus (Qiagen) |

### Table 1 (continued)

Comparison of various approaches used for the purification of HIV-1 trimers

| Production and Characterization of HIV-1 Envelope Trimers | 2G12 | Foldon | Strep-Tag II |
|----------------------------------------------------------|------|--------|-------------|
| **Ligand**                                               | BnAb | Ni (or a heavy metal such as Co) | Modified streptavidin, referred to as Strep-Tactin, attached to solid matrix |
| **gp140**                                               | Wild-type | The 27-aminoo acid trimerization motif, referred to as foldon or fibritin, followed by His-tag fused to the C-terminus of gp140 | The 8-aminoo acid Strep-Tag II peptide with a 27-aminoo acid linker fused to the C-terminus of gp140 |
| **Specificity**                                         | Low, broad | High, narrow | High |
| All molecules (not only proteins) containing mannose captured | Requires epitope containing a1–2-linked mannoses in an appropriate structural context; envelope proteins of variant HIV viruses lacking the epitope may not be captured; these must be mutated to create a binding site for 2G12 BnAb (28,67) | Binds to hexa- or octa-histidine tag at the C-terminus | Binds to Strep-Tag II at the C-terminus |
| **Elution**                                             | Strong reagent (1 M mannose) | Strong reagent (3 M MgCl2) | Strong reagent (200–400 mM imidazole) |
| **Purity**                                              | In addition to gp120, gp140 protomers (monomers and dimers) and trimers, mannose-containing non-target molecules will also be captured and co-purified; the purified sample therefore may contain significant amounts of these contaminants | Captures only the envelope protein molecules containing the 2G12 epitope; these include gp120, gp140 protomers (monomers and dimers) and trimers | In addition to His-tag containing gp140 proteins (monomers and dimers) and trimers, Ni can nonspecifically bind to non-target contaminating proteins |
| **End specificity**                                      | No | No | Yes |
| Does not discriminate between the full-length gp140 molecules and gp120 or truncated products of gp140; the latter would remain as contaminants | Does not discriminate between the full-length gp140 molecules and gp120 or truncated products of gp140; the latter would remain as contaminants | Since binding requires the C-terminally fused tag, the purified sample essentially contains full-length gp140 molecules; gp120 and most of the truncated products will be excluded by the column | Since binding requires the C-terminally fused tag, the purified sample essentially contains full-length gp140 molecules; gp120 and most of the truncated products will be excluded by the column |
| **Quality of trimers**                                   | Medium | High | Low |
| The co-purified contaminants might affect the quality of the trimers | High percentage (>90%) of three-blade propeller shaped trimers demonstrated with cleaved BG505 gp140 | Primarily used for production of uncleaved trimers; trimers are irregular shaped and non-specifically crosslinked | High percentage (>90%) of three-blade propeller shaped trimers demonstrated with cleaved JRFL gp140 |
| **Stripping**                                           | Not reported | Not reported | Yes |
| Contaminants nonspecifically bound to the column cannot be completely stripped off using conventional reagents such as urea or NaOH as these will denature the lectin; washing with high salt buffers can strip some of the contaminants | Can be stripped with EDTA, urea, or NaOH multiple times | Can be stripped with NaOH multiple times |
| **Re-use**                                               | Limited | Limited | High |
| Can be re-used but the binding capacity significantly reduced after each use | Not reported | Can be stripped and re-used multiple times without significantly losing the binding capacity. | Can be stripped and re-used multiple times without significantly losing the binding capacity. |
| **Capacity**                                            | Low to Medium | Low to Medium | Low |
| 3 mg ligand/ml | 50 mg ligand/ml | 9 mg ligand/ml | |
| **Cost**                                                | $130 for 2 ml or 6 mg of Galanthus nivalis lectin GNL (Vector Laboratories) | $565 for 1 mg of 2G12 Ab (Polymun Scientific) | $23 for 2 ml of Ni-NTA Agarose (Qiagen) |
| Cost would be higher than the amount shown because independent columns may need to be used for purification of different gp140 proteins to avoid cross-contamination | Cost might be higher, but more information is needed on the efficiency of 2G12 coupling to beads and reusability of the column | Since complete stripping can be done, the same column can be re-used for purification of a different gp140 protein; cross contamination, if any, would be minimal | Since complete stripping can be done, the same column can be re-used for purification of a different gp140 protein; cross contamination, if any, would be minimal |
Negative stain EM of trimers produced by the above approaches showed heterogeneous mixtures of particles. Relatively few were classic three-blade propeller-shaped, and some (e.g. the JRFL foldon trimers) showed variably shaped particles (Fig. 1), although almost all of these preparations behaved as “true” trimers by SEC and BN gel electrophoresis (Table 1). Extended Strep-tag II Allows Efficient Isolation of gp140—We concluded that an approach that allows selective capture of gp140 directly from the culture medium would be most desirable for the production of trimers. Previous attempts to achieve this by fusing gp140 with a tag, such as the His tag, have failed. We hypothesized that these failures stemmed from the possibility that the tag, when attached to the base of the gp140 structure, was probably occluded, a problem further compounded by the presence of glycan shield, with up to 12 glycans attached to the C-terminal heptad repeat 2 (HR2) helices (see below). If our hypothesis was correct, extending the tag away from the base should make it more accessible for binding. The finding that the insertion of a 27-aa foldon sequence between the C terminus of gp140 and the His tag allowed efficient binding to nickel-agarose supported this reasoning.

We constructed a series of 36 recombinant clones by fusing the gp140 C terminus to Strep-tag II and octahistidine tag with various linkers in the middle (Fig. 2, A and B). Strep-tag II is an 8-aa peptide (WSHPQFEK) that binds to modified streptavidin, namely Strep-Tactin, at micromolar affinity and stringent specificity. However, the complex can be dissociated with desthiobiotin, a mild condition. We chose clade B JRFL gp140 as a template to evaluate this approach, but we also constructed, in parallel, clade A BG505 gp140 clones for comparison. Three “SOSIP” mutations and five “stabilizing” mutations were introduced to stabilize JRFL trimers (50, 51). The A501C and T605C mutations create an intraprotomer disulfide bond between gp120 and gp41, and the I559P mutation in the HR1 helix strengthens intersubunit (gp41) interactions, whereas the five mutations in or near HR1 (1535M, Q543L, S553N, K567Q, and R588G) strengthen gp120 and gp41 interactions at the interface (50–52).

Our data demonstrate that the Strep-tag II approach is highly effective to capture gp140 from the culture medium. Strep-tagged gp140 with a short Ala3 (or Gly-Ser-Gly-Ser) linker bound poorly to Strep-Tactin (Fig. 2C, lane 3), whereas the Twin Strep-tag containing 23-aa linker was efficiently captured by Strep-Tactin-purified gp140 samples. Lanes labeled M, M′, markers. The molecular masses in kDa of the marker proteins are shown on the left. Gels in C, D, E, and G were stained with Coomassie Blue.
Production and Characterization of HIV-1 Envelope Trimers

FIGURE 3. Truncations beyond aa 664 produce few or no gp140 trimers. A, a screening strategy to optimize recombinant gp140 production. B, D, and E, the secreted gp140 was captured by adding Strep-Tactin beads to the culture medium and eluted with 2.5 mM desthiobiotin. The same amount of the eluted sample was used to determine the efficiency of expression (B), cleavage and gp41 glycosylation (D), and trimer production (E). C, the efficiency of expression was further assessed by directly using the supernatant without the addition of Strep-Tactin beads. The samples were electrophoresed under reducing conditions so that gp41 would be cleanly separated and fully available for interaction with the Strep-tag mAb used for Western blotting. 

The CR gp140 was further confirmed by Western blotting using a highly sensitive Strep-tag-specific mAb (Fig. 2C). The same amount of the supernatant was used to determine the efficiency of expression (Fig. 3B). The samples were electrophoresed under reducing conditions (Fig. 2C), whereas CR664-gp140 produced more dimers than trimers (lane 2). Similar patterns were also seen with Strep-tagged BG505 gp140. However BG505 produced higher levels of uncleaved trimers (lane 4, compare with lane 2), and the trimer bands were more diffused than JRFL, indicating more extensive glycosylation, as also evidenced by slightly higher M, of these bands (lanes 3 and 4, compare with lanes 1 and 2).

Truncation of Cleaved gp140 beyond aa 664 Results in Poor gp140 Production—We developed a rapid screening strategy to optimize various parameters for maximal trimer production, using any HIV-1 Env sequence (Fig. 3A). More than 40 different Strep-tagged gp140 clones were constructed, and each was transfected into a small volume (6 ml) of cells. The secreted gp140 was captured by adding Strep-Tactin beads directly to the culture medium, and the efficiency of expression (Fig. 3B), cleavage (Fig. 3D), and trimer production (Fig. 3E) was analyzed. The efficiency expression was further assessed by directly using the supernatant without Strep-Tactin purification (Fig. 3C). Different parameters tested include point of truncation, importance of SOSIP mutations and cleavage, production in 293F or GnTI- cells (GnTI- cells lack N-acetylglycosaminetransferase 1 and cannot introduce complex glycosylations), and clade B (JRFL) and A (BG505) gp140 (an N-glycosylation site was introduced into BG505 at aa 332 to make it equivalent to JRFL gp140) (62).

---

\[3\] N. Ananthaswamy, W. Alsalmi, M. Mahalingam, and V. B. Rao, manuscript in preparation.
We observed similar patterns with both JRFL and BG505 gp140s expressed in 293F or GnTI- cells. SOSIP mutations proved essential because without them, most of the protein aggregated and could not be captured by Strep-Tactin. Unexpectedly, however, we found that cleaved gp140 truncated beyond aa 664 produced lower amounts of gp140 in the culture medium (Fig. 3, B and C). The aa 672 and aa 683 constructs produced 3–5 times lower amounts, whereas further truncation resulted in nearly complete loss of gp140 production (Fig. 3C). This was not due to poor cleavage because 683-gp140 was efficiently cleaved, producing, as expected, slightly larger gp41 ladder bands (Fig. 3D, lane 2, compare with lane 1). In contrast, production of uncleaved 683-gp140 was not significantly affected. Unlike the cleaved 683-gp140, which was expressed at lower levels (Figs. 2D (compare lanes 9–12 with lanes 13–16) and 3B (lanes 2 and 6)), the expression of uncleaved 683-gp140 was nearly as high as 664 (Fig. 3B, lanes 3 and 7 versus lanes 4 and 8). Finally, the aa 683 protein showed a tendency to aggregate, as shown by its appearance largely as a high M₈ smear in the BN gel (Fig. 3E, lane 3).

The above results suggest that cleavage triggers a conformational change in the MPER, which might lead to exposure of some of the hydrophobic residues, leading to aggregation. This hypothesis is consistent with the previous reports by Klasse et al. (63) and Ringe et al. (26), which showed that the cleaved aa 681 (from KNNH1144) and aa 683 (from BG505) gp140 proteins formed micelles at the MPER, presumably through interaction of the exposed hydrophobic residues of MPER with the lipid components.

Cleavage Is Essential for Production of Authentic HIV-1 Trimers—Strep-Tactin-purified gp140 was ~95% pure (Fig. 4A, 1), but it contained a mixture of trimers and protomers as well as some high M₈ species (Fig. 4A, lane 5). SEC separated these into three major fractions (Fig. 4A, 2): (i) a high M₈ fraction that eluted immediately after the void volume and migrated as a diffuse band on BN gel (A.3, lane 1); (ii) trimers, which eluted as a relatively sharp peak and migrated as a compact band on BN gel (lane 2); and (iii) two overlapping peaks of protomer dimers and monomers (lane 3). To determine which of the trimers were authentic, cleaved or uncleaved, 293F-produced (complex glycans) or GnTI-produced (high mannose, no complex glycans) trimers were expressed on a large scale (1–4 liters) and purified by Strep-Tactin capture and SEC. The yields of gp140 were as follows: 293F CR, ~20 mg/liter; CP, ~12 mg/liter; GnTI- CR, ~3 mg/liter; CP, ~1 mg/liter. Each SEC fraction was then analyzed by SDS-PAGE under reducing conditions to assess purity and cleavage (Fig. 4, B, C, D, and E) (panels 2), BN-PAGE to assess oligomeric state (panels 1), negative EM to assess the shape of the trimer (panels 3–5), and antigenicity to assess conformation (see below). These analyses showed that the trimers were purified to near homogeneity, up to 2–3 mg/liter (CP trimers), as well as establishing the criteria for their authenticity. First, we observed that in the case of JRFL Env, the fraction of gp140 recovered as trimers was 3–5-fold greater with cleaved gp140 than with uncleaved gp140 (compare lanes 5 and 7 of B.1 with D.1). Second, the uncleaved trimers were of poor quality when compared with the cleaved trimers. Unlike the CP trimer fractions that showed a sharp band on the BN gel (B.1, lanes 3–7), the CR trimer fractions contained significant levels of diffused and high M₈ species (D.1, lanes 3–7). The latter represented conformationally heterogeneous molecules, as was also evident from their poor reactivity with the conformation-specific NbAb PGT145 (Fig. 5). The reactivity was lowest with fractions containing the highest amount of these species. Third, the protomers of the uncleaved trimers as well as the foldon trimers were nonspecifically cross-linked through disulfide bonds, whereas the cleaved trimers showed much less cross-linking (Fig. 6). Fourth, the uncleaved trimers were more susceptible to nonspecific proteolysis, as evidenced by greater proteolysis of the CR trimers by Proteinase K than the CP trimers (Fig. 7). Finally, negative stain EM showed that the cleaved trimers appeared as three-blade propeller-shaped particles (Fig. 4, B and C, panels 3 and 4; reference-free two-dimensional class averages are shown in panels B.6 and C.7), whereas the CR fractions showed fewer such particles (D and E; panels 3–5), and most were irregularly shaped. Overall, the above results are consistent with the behavior of the uncleaved and cleaved trimers generated by the 2G12 approach (see Table 1) (26).

Uncleaved Trimers Are Hyperglycosylated—We observed that GnTI- cells produced better quality trimers than the 293F cells, although the yields were lower in GnTI- cells (Fig. 4, compare panels in C and E with the same panels in B and D). For instance, the diffused high M₈ species described above were not seen in the CR trimers produced by GnTI- cells (compare D.1 and E.1, lanes 1–7). Negative stain EM showed a higher number of propeller-shaped trimers in the GnTI-—produced CR trimers than in the 293F—produced trimers (compare panels 3–5 in D and E), which, in part, was due to heterogeneity in glycosylation. GnTI- cells predominantly add Man5GlcNac2, which is further processed by complex glycosylation in 293F cells. The presence of Strep-tag II at the C terminus of gp41 allowed evaluation of glycosylation using Strep-tag-specific mAbs. A ladder of five gp41 bands appeared when CPgp140 trimers were electrophoresed under reducing conditions. Of these, band 3 showed maximum intensity (Fig. 8, A.1 and A.2). Because the JRFL gp41 ectodomain contains a cluster of four predicted N-linked glycosylation sites near its C terminus, these bands probably corresponded to glycosylation of 0–4 sites. This was confirmed by deglycosylation with PNGase F, which converted the ladder to a single species that migrated to the same position as the lowest band in the ladder, the unglycosylated gp41 (Fig. 8A.3, lanes 2, 4, 6, and 8). Although a similar pattern was observed in both 293F and GnTI- cells, the fully glycosylated 293F—gp41 bands were more diffused than the same from GnTI-—gp41 (Fig. 8A.3, compare lanes 1–3 and 5–7), presumably due to complex glycosylation. BG505 CP-gp140 showed similar banding patterns except that it appeared to undergo more extensive glycosylation. These results demonstrate “microheterogeneity” in gp41 glycosylation, albeit to a higher extent in 293F cells than in GnTI- cells. Heterogeneity of gp41 glycosylation was also inferred in previous reports (64, 65).

The heterogeneity was more severe with the uncleaved trimers. Indeed, the uncleaved trimers produced by 293F cells were “hyperglycosylated.” Under non-reducing conditions, both the CP gp140 and CR gp140 were expected to migrate at the same
position. They indeed did so when gp140 was produced by the GnTI^- cells (Fig. 8B.1, lanes 3 and 4). The 293F gp140 migrated slower than the GnTI^- gp140 (compare lane 1 with lane 4 and lane 2 with lane 3), which was expected because gp140 undergoes complex glycosylations in 293F cells. Unexpectedly, however, the 293F-produced CR gp140 migrated slower than CP gp140 (compare lanes 1 and 2). Upon deglycosylation with PNGase F, all gp140 bands, whether uncleaved or cleaved, produced in 293F or GnTI^- cells, migrated at the same position (Fig. 8B.2). The same pattern was also observed with the BG505 gp140 tested in parallel (see BG505 lanes 5–8 in Fig. 8). These results demonstrated that the 293F uncleaved trimers were hyperglycosylated when compared with their cleaved counterparts.

Antigenic Signatures Discriminate between Uncleaved and Cleaved Trimers—We have used an ELISA platform that can differentiate the structural and conformational states of cleaved and uncleaved trimers. Purified gp140 proteins were coated on Strep-Tactin plates through the C-terminal Strep-tag and incubated with mAbs that recognize different conformational signatures (Fig. 9). Because coating was done at neutral pH (unlike at pH 9 in traditional ELISAs), it would cause minimal, if any,
structural perturbation. Moreover, the trimers were immobilized at a defined point; therefore, all immobilized molecules should be exposed in a similar orientation, in some ways mimicking the Env spikes displayed on the HIV-1 virion. Finally, the 23-aa flexible linker should make the trimer more accessible to Ab binding.

FIGURE 5. Conformational heterogeneity of uncleaved trimers produced in 293F cells. SEC fractions 2–5 from Fig. 4D.1 were coated on Strep-Tactin plates at a fixed protein concentration of 1 µg/ml, and ELISAs were performed using the BnAbs 2G12 (black bars) or PGT145 (blue bars). Inset, Coomassie Blue-stained BN gel of fractions 2–5 depicting the presence of various amounts of smear in the fractions. The smear represents differential migration of conformationally heterogeneous trimers on the BN gel. Note the poor reactivity of fraction 2 containing an extensive smear to the conformation-specific PGT145 BnAb when compared with fraction 5 with a lesser smear. On the other hand, the 2G12 BnAb, which is not dependent on the conformation of the trimer, reacted equivalently to both fractions 2 and 5.

FIGURE 6. The protomers of uncleaved trimers are nonspecifically cross-linked with disulfide bonds. The SEC-purified JRFL trimers (Strep-tag uncleaved (CR), foldon-uncleaved (FD), and Strep-tag cleaved trimers (CP)) were electrophoresed under non-reducing (A) or reducing (B) conditions without (lanes 1, 3, 5, 7, 9, and 11) or with (lanes 2, 4, 6, 8, 10, and 12) PNGase F treatment. Note the presence of a ladder of high M bands in the FD uncleaved and Strep-tag uncleaved trimers (red arrows in lanes 1 and 3) but not in the cleaved trimers (lane 5). That these bands correspond to nonspecific disulfide cross-linked protomers, but not to differences in glycosylation, was shown by electrophoresis under reducing conditions and treatment with PNGase F. All of the high M bands were converted to a single band under reducing conditions (lanes 7 and 9), but the ladder remained after PNGase treatment (lanes 2 and 4), although the deglycosylated (DG) bands migrated faster due to the removal of glycans (when compared with lanes 1 and 3). The cleaved trimers did not show the high M ladder bands under non-reducing conditions (lane 5) and, as expected, converted to a faster-migrating DG band after PNGase F treatment (lane 6). Under reducing conditions, as expected, the cleaved trimers gave rise to gp120 and a ladder of gp41 bands (lane 11) and faster-migrating DG gp120 and single DG gp41 band (lane 12) after PNGase F treatment.

FIGURE 7. Proteinase K sensitivity of cleaved and uncleaved JRFL trimers. A, SEC-purified trimers from 293F or GnTI− cells were treated with Proteinase K at the indicated concentrations for 1 h at 37 °C and electrophoresed on a reducing SDS gel followed by Coomassie Blue staining. The 37 °C lane corresponds to control sample incubated at 37 °C for 1 h without Proteinase K. Note that the uncleaved trimers are more susceptible to proteolysis than the cleaved trimers and also that the 293F trimers are more susceptible to proteolysis than the GnTI− trimers. B, densitometric quantification of the undigested gp140 bands from A.

We first tested the reactivity of the trimers to BnAbs 2G12, VRC01, and PGT121. 2G12 recognizes a discontinuous epitope consisting of three or four high mannose glycans in the gp120 domain (66, 67). VRC01 is a potent BnAb that binds to the CD4 binding site and neutralizes >90% of the primary HIV-1 isolates (17). PGT121 primarily recognizes the complex glycan attached to Asn-332 (62). Consistent with the published data indicating that the conformational epitopes recognized by these Abs are well exposed in trimers as well as in gp120, both our cleaved and uncleaved trimers reacted strongly and equivalently to these Abs (Fig. 9) (23, 26, 28, 31, 68).

The BnAb PGT151 recognizes a conformational epitope containing aa residues and glycans present at the interface of gp120 and gp41 that is better exposed in the cleaved trimers (69, 70). Our results showed that the cleaved gp140 trimers exhibited stronger reactivity to PGT151 than the uncleaved trimers, suggesting that our cleaved trimers achieved native-like conformation.

The BnAbs PG16 and PG9 are quaternary Abs that neutralize 70–80% of the primary HIV-1 viruses. The quaternary specificity stems from their long hammerhead-shaped complementarity-determining region, which asymmetrically interacts with the V1, V2, and V3 loops of two protomers of the same trimer. The contact regions include, primarily, the V1/V2 loop glycans Asn-160 and Asn-156/173, and residue Lys-168 of one protomer and glycans Asn-160 and Asn-197 (V3 loop) of the adjacent protomer (29, 71, 72). PGT145 is also a quaternary BnAb, however less well characterized, and it, like PG9 and PG16, recognizes the Asn-160 and Asn-156/173 glycans (42,
Consistent with the expectation that a compact trimer would react better with the quaternary Ab, the cleaved trimers reacted more strongly with PG9, PG16, and PGT145 BnAbs than the uncleaved trimers (Fig. 9).

Finally, the reactivity of our trimers with the non-neutralizing Abs (NnAbs) b6, F105, and F240 was tested. F105 and b6 recognize an epitope that includes the CD4 binding site, whereas F240 binds to the immunodominant loop of gp41 (aa 592–604) (16, 43, 73–75). Our CR and CP trimers as well as our protomers reacted similarly with these NnAbs, although the reactivity with F240 was poor overall, probably because its epitope is partially occluded (Fig. 9, green epitope signature).

Collectively, these data demonstrate that our trimers display antigenic signatures that are consistent with their cleaved or uncleaved states. Differential reactivity with the quaternary epitopes provides the best benchmark to ascertain the antigenic signature of compact, native-like trimers.

**Discussion**

The trimeric envelope spike of HIV-1 virion makes the first contact with the host cell. It triggers fusion of viral and host membranes and delivers the nucleocapsid core into the cell. Trimer-specific Abs could disable Env function and block transmission of HIV. Development of a recombinant trimer immunogen, therefore, is one of the highest priorities in the hunt for an effective HIV vaccine (26, 32, 76). However, a myriad of variations reported in the literature led to confusion and controversy, and none could be effectively applied to diverse strains of HIV. For instance, recently, a procedure that produced native-like trimers from A-clade BG505 by using 2G12 BnAb to capture gp140 was not as effective with the B-clade JRFL trimers (26, 76). Hence, another procedure was developed in which lectin capture and negative selection by F105 NnAb was used to purify trimers (76). These Ab-based approaches have inherent limitations because the epitope signatures might vary from one HIV clade to another. In fact, it was necessary to mutate the wild-type BG505 gp140 in order to create the 2G12 binding epitope and allow for its purification by the 2G12 BnAb (26, 31). Here, we report a new approach that allows production of HIV Env trimers from potentially any HIV-1 clade or strain.

We further present systematic analyses to optimize trimer production and biochemical characterizations to define the signatures of trimers.

A key feature of our approach is to selectively capture gp140 Env directly from the culture supernatant under mild conditions that cause minimal, if any, perturbation to the structure or oligomeric state of the protein. Attempts to achieve this using an affinity tag have thus far failed because the tag was not accessible for interaction with its binding partner. In accordance
with the recent x-ray structures, the C-terminal aa 664 would not be accessible because it is the last residue of the long HR2 helices that encircle the base of the gp140 trimer (29, 70). It is further shielded by as many as 12 glycans emanating from these helices (29, 70). Therefore, it was essential not only to incorporate an exquisitely specific Strep-tag II but also to separate the tag from the base by a /H11022 20-aa-long linker. These modifications avoided clashes with the trimer base and allowed purification of nearly homogeneous protein in a single step. A variety of gp140 variants, cleaved, uncleaved, GnTI /H11002 -glycosylated, and 293F glycosylated from clades A, B, and A-E viruses, could be purified by this approach.

The Strep-tagged gp140 proteins behaved similarly to the native gp140. For instance, the CP gp140 was nearly completely cleaved to gp120 and gp41, and the CR gp140 remained uncleaved. SOSIP mutations were essential; otherwise, most of the gp140 aggregated into a high Mr fraction. Curiously, gp41 glycosylation was heterogeneous, showing five gp41 bands corresponding to glycosylation of 0–4 sites of the four N-linked glycosylation sites clustered in or near the 34-aa-long HR2 helix. This microheterogeneity, which was observed in both JRFL and BG505 gp140, might reflect a competition between the rate of glycosylation and the rate of folding of this transiently exposed structural element.

Our results show that cleavage is not essential for trimerization per se, but it is essential for maturation into propeller-shaped particles. Uncleaved gp140 produced such native-like particles but in fewer and variable numbers. Maturation might involve two, probably sequential, events, conformational transition and complex glycosylation (77). A cleavage-triggered conformational transition can be deduced from our experiments. Truncated CP gp140 constructs beyond aa 664 (e.g. aa 683) produced 3–5 times lower amounts of gp140, whereas the same truncation in a CR background was not significantly affected, and much of the aa 683 protein aggregated. Thus, the conformation of MPER where these residues are located must be different in the cleaved and uncleaved states. These results are consistent with the previous reports by Klasse et al. (63) and Ringe et al. (26), which showed that the cleaved aa 681 and aa 683 proteins formed micelles at the MPER. Perhaps some of the residues in the hydrophobic residue-rich MPER are better exposed in the cleaved state and associate with the membrane. Structural studies suggest that the MPER forms an L-shaped bent helix, and the residues 675–683 contact the virion membrane (78). Second, cleaved trimers exhibited greater stability and are less susceptible to proteolysis than the uncleaved trimers, suggesting that cleavage renders the trimers more compact and less accessible to protease. Finally, negative stain EM showed compact, propeller-shaped “blobs” in the uncleaved state, as was also observed by Ringe et al. (26) with the 2G12 produced trimers (Table 1).

Careful analysis of glycosylation patterns showed that cleavage channels trimers into the correct glycosylation pathway. Without cleavage, trimers from both JRFL and BG505 enter an aberrant pathway, resulting in hyperglycosylation, which traps the trimers in a loosely associated state. Consequently, the uncleaved trimers, including the foldon trimers produced by 293F cells, are conformationally heterogeneous, nonspecifically cross-linked, more susceptible to proteolysis, and irregularly...
Production and Characterization of HIV-1 Envelope Trimers

TABLE 2
Reactivity of various cleaved and uncleaved trimers with non-neutralizing antibodies using different assay platforms

| Construct | Composition | Cleavage | b6  | F105 | F240 | References |
|-----------|-------------|----------|-----|------|------|------------|
| ELISA     |             |          |     |      |      |            |
| 1. BG505.SOSIP.R6.664 Trimer CP | CP | +++   | +   | ++   | 26, 28 |
| 2. BG505.WT.SEKS.664 Trimer CR | CR | ++++  | +++ | +++  | 26    |

| SPR       |             |          |     |      |      |            |
|-----------|-------------|----------|-----|------|------|------------|
| 3. BG505.SOSIP.R6.664 Trimer CP | CP | -/+   | NR  | -    | 26, 28, 31 |
| 4. BG505.SOSIP.SEKS.664 Trimer CR | CR | +     | NR  | -/+  | 26, 31  |
| 5. BG505.WT.SEKS.664 Trimer CR | CR | +++   | NR  | ++   | 26, 31  |

| Bio-layer interferometry |             |          |     |      |      |            |
|-------------------------|-------------|----------|-----|------|------|------------|
| 6. BG505.SOSIP.R6.664 Trimer CP | CP | ++   | -   | NR  | 70    |
| 7. JRFL.SOSIP.R6.663 Trimer CP | CP | ++++ | ++  | NR  | 76a  |
| 8. 16055.SOSIP.R6.663 Trimer CP | CP | ++++ | ++  | NR  | 76a  |

* Before negative selection.

The presence of a diffuse smear in the native gel, poor reactivity with the conformation-specific PGT145 BnAbs, and heterogeneity in gp41 complex glycosylations provide further evidence of this phenotype. Finally, the uncleaved trimers from GnTT− cells that are unable to carry out hyperglycosylations showed a higher percentage of native-like trimers, further underscoring the negative effects of hyperglycosylation.

The strong reactivity of our CR and CP trimers with the BnAbs 2G12, VRC01, and PGT121 confirmed that the Strep-tagged trimers have correctly folded gp120 and gp41 ectodomains, exposing the respective conformational epitopes. Preferential reactivity of the cleaved trimers with the PGT151 NbAb further confirmed the integrity of the conformational epitope that emerges at the interface of gp120 and gp41 following cleavage. Strong reactivity with cleaved trimers, but not with uncleaved trimers, of the quaternary BnAbs PG9 and PG16 demonstrated that our CP gp140 protomers assembled into correct quaternary structure. Contrary to some reports that the CR trimers, but not the CP trimers, react with the NnAbs, both of our CR and CP trimers reacted similarly with the NnAbs b6, F240, and F105 (31). Careful examination of the published reports, however, showed that the reactivity depended on the type of assay platform used, and the sequences of the CR and CP trimers compared were not identical (Table 2). On the other hand, our data were generated using identical CP and CR sequences (except for the cleavage site), and our Strep-Tactin-based ELISA platform is not expected to introduce significant structural perturbations into the trimeric antigens. Furthermore, the HIV Env trimer is a dynamic structure and probably oscillates between "closed" and "open" states, allowing the NnAb to interact with the trimer when it opens transiently (79, 80). Thus, strong reactivity to the quaternary-specific BnAbs, such as PG9 and PG16, is the most reliable benchmark to assess the authenticity of the native-like trimers.

In conclusion, we have developed a new system to produce, optimize, and characterize pure and native-like HIV-1 Env trimers. Both cleavage and proper glycosylation are critical to generate compact, three-blade propeller shaped particles, whereas without cleavage, the trimers are heterogeneous in conformation, nonspecifically cross-linked, and hyperglycosylated, properties consistent with their irregular shape. The GnTI− cells produced better quality trimers than the 293F cells. However, the 293F trimers might better recapitulate the native structure because GnTI− cells lack complex glycosylations. The caveat, however, is that we do not know the glycan structures introduced by the 293F cells and whether these are the same as that present on the HIV-1 virion. Microheterogeneity of glycosylation might also be a concern. Three criteria, namely ≥95% cleavage, nearly 100% propeller-shaped particles, and strong reactivity to quaternary BnAbs, define authentic HIV-1 trimers. We believe that the Strep-tag approach provides several useful features (Table 1) and is broadly applicable to generate trimers from potentially any HIV-1 virus for basic research as well as for human clinical trials and vaccine manufacture. The well behaved JRFL trimers described here might serve as a good scaffold for further engineering to generate a trimeric immunogen that can elicit transmission-blocking Abs against diverse HIV-1 strains.

Author Contributions—W. A., C. H., D. F., and G. G. constructed the recombinants and did the cell culture work. W. A., M. M., and N. A. purified proteins. W. A. did glycosylation studies, and M. M. did the ELISA work. V. B. R. designed the research and wrote the manuscript with the assistance of W. A., N. A., and M. M.

Acknowledgments—We are grateful to Dr. Sriram Subramaniam and his colleagues from NCI, National Institutes of Health, for many discussions to overcome problems in trimer production. In particular, we thank Drs. Giovanna Grandinetti and Soojay Banerjee for kind assistance. We thank Dr. Grandinetti for all of the negative stain EM performed during this work. We thank Dr. Sriram Subramaniam and Dr. Mangala Rao (Walter Reed Army Institute of Research, Silver Spring, MD) for discussions throughout this investigation and Dr. Ayça Akal-Strader (Catholic University of America) for a careful review of the manuscript.

References

1. Kwong, P. D., and Mascola, J. R. (2012) Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412–425
2. Mascola, J. R., and Nabel, G. J. (2001) Vaccines for the prevention of HIV-1
of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J. Virol. 86, 13152–13163
21. Yu, L. and Guan, Y. (2014) Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front. Immunol. 5, 250
22. Esparza, J. (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31, 3502–3510
23. Chakrabarti, B. K., Feng, Y., Sharma, S. K., McKee, K., Karlsson Hedestam, G. B., Labranche, C. C., Montefiori, D. C., Mascola, J. R., and Wyatt, R. T. (2013) Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J. Virol. 87, 13239–13251
24. Kovacs, J. M., Nkoloka, J. P., Peng, H., Cheung, A., Perry, J., Miller, C. A., Seaman, M. S., Barouch, D. H., and Chen, B. (2012) HIV-1 envelope trimers elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. U.S.A. 109, 12111–12116
25. Nkoloka, J. P., Cheung, A., Perry, J. R., Carter, D., Reed, S., Schuitemaker, H., Pau, M. G., Seaman, M. S., Chen, B., and Barouch, D. H. (2014) Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimers. Vaccine 32, 2109–2116
26. Ringe, R. P., Sanders, R. W., Yasmeen, A., Kim, H. J., Lee, J. H., Cupo, A., Korzun, J. Derking, R., van Montfort, T., Julien, J. P., Wilson, I. A., Klasse, P. J., Ward, A. B., and Moore, J. P. (2013) Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. U.S.A. 110, 18256–18261
27. Liao, H. X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A. Z., Zhang, Z., Zhu, J., Shapiro, L. N. S. Comparative Sequencing Program, Mullinik, J. C., Gnanakaran, S., Kraber, R., Wiehe, K., Kelsoe, G., Yang, G., Xia, S. M., Montefiori, D. C., Parks, R. Lloyd, E. K., Searce, R. M., Soderberg, K. A., Cohen, M., Kamanga, G., Louder, M. K., Tran, L. M., Chen, Y., Cai, F., Chen, S., Moquin, S., Du, X., Joyce, M. G., Srivatsan, S., Zhang, B., Zheng, A., Shaw, G. M., Hahn, B. H., Kepler, T. B., Korber, B. T., Kwong, P. D., Mascola, J. R., and Haynes, B. F. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469–476
28. Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., Kim, J. H., Blattner, C., de la Peña, A. T., Korzun, J., Golabek, M., de Los Reyes, K., Ketas, T. J., van Gils, M. J., King, C. R., Wilson, I. A., Ward, A. B., Klasse, P. J., and Moore, J. P. (2013) A next-generation cleaved soluble HIV-1 Env Trimer. BG505 SOSIP.664 gp140 expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618
29. Julien, J. P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P. J., Burton, D. R., Sanders, R. W., Moore, J. P., Ward, A. B., and Wilson, I. A. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimmer. Science 342, 1477–1483
30. Lyumkis, D., Julien, J. P., de Val, N., Cupo, A., Potter, C. S., Klasse, P. J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., Wilson, I. A., and Ward, A. B. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimmer. Science 342, 1484–1490
31. Yasmeen, A., Ringe, R., Derking, R., Cupo, A., Julien, J. P., Burton, D. R., Ward, A. B., Wilson, I. A., Sanders, R. W., Moore, J. P., and Klasse, P. J. (2014) Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleved Env proteins, and monomeric subunits. Retrovirology 11, 41
32. Pugach, P., Ozorowski, G., Cupo, A., Ringe, Y., Yasmeen, A., de Val, N., Derking, R., Kim, H. J., Korzun, J., Golabek, M., de Los Reyes, K., Ketas, T. J., Julien, J. P., Burton, D. R., Wilson, I. A., Sanders, R. W., Klasse, P. J., Ward, A. B., and Moore, J. P. (2015) A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 89, 3380–3395
33. Gao, G., Wieczorek, L., Peachman, K. K., Polonis, V. R., Alving, C. R., Rao, M., and Rao, V. B. (2013) Designing a soluble near full-length HIV-1 gp140 trimer. J. Biol. Chem. 288, 234–246
34. Tao, P., Mahalingam, M., Marasa, B. S., Zhang, Z., Chopra, A. K., and Rao, V. B. (2013) In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. Proc. Natl. Acad. Sci. U.S.A. 110, 5846–5851
35. Sathiyalayala, T., Rao, M., Maclean, D. M., Birx, D. L., Alving, C. R., and Rao, V. B. (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multi-
Production and Characterization of HIV-1 Envelope Trimers

Neutralization of HIV-1 by F105, a human monoclonal antibody to the epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.

Emanuele Cavacini, Luciana A. Toi, Massimiliano Penna, Marios Panoutsos, and Martin Sodroski (2007) Production and Characterization of HIV-1 Envelope Trimers. J. Virol. 81, 11106–11116.

Neutralization of HIV by multiple highly potent antibodies.

Wilson, I. A., Burton, D. R., and Poignard, P. (2011) Broad neutralization of HIV-1: a single potent antibody is sufficient to cover the envelope glycoprotein gp120. Nature Struct. Mol. Biol. 18, 796–803.

Higuchi, R., Krummell, B., and Saiki, R. K. (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16, 7351–7367.

Stemmer, W. W. (1994) In vitro selection of enzymes with improved properties. Nature 370, 389–391.

Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., and Ludtke, S. J. (2007) EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38–46.

Tran, K., Poulsen, C., Guengan, J., de Val Alda, N., Wilson, R., Sundling, C., Li, Y., Stanfield, R. L., Wilson, I. A., Ward, A. B., and Wyatt, R. T. (2014) Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. U.S.A. 111, 13413–13418.
Production and Characterization of HIV-1 Envelope Trimers

Depe tris, R. S., Julien, J. P., Khayat, R., Lee, J. H., Pejchal, R., Katpally, U., Cocco, N., Kachare, M., Massi, E., David, K. B., Cupo, A., Marozsan, A. I., Olson, W. C., Ward, A. B., Wilson, I. A., Sanders, R. W., and Moore, J. P. (2012) Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J. Biol. Chem. 287, 24239–24254

Guttmann, M., Garcia, N. K., Cupo, A., Matsui, T., Julien, J. P., Sanders, R. W., Wilson, I. A., Moore, J. P., and Lee, K. K. (2014) CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22, 974–984

Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., and Moore, J. P. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293–7305

Murin, C. D., Julien, J. P., Sok, D., Stanfield, R. L., Khayat, R., Cupo, A., Moore, J. P., Burton, D. R., Wilson, I. A., and Ward, A. B. (2014) Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J. Virol. 88, 10177–10188

Pancera, M., and Wyatt, R. (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332, 145–156

Blattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A. T., Cupo, A., Julien, J. P., van Gils, M., Lee, P. S., Peng, W., Paulson, J. C., Poignard, P., Burton, D. R., Moore, J. P., Sanders, R. W., Wilson, I. A., and Ward, A. B. (2014) Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669–680

Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G. Y., Olek, G., Stewart-Jones, G. B., Stuckey, J., Baier, R. T., Joyce, M. G., Louder, M. K., Tumba, N., Yang, Y., Zhang, B., Cohen, M. S., Haynes, B. F., Mascola, J. R., Morris, L., Munro, J. B., Blanchard, S. C., Mothes, W., Connors, M., and Kwong, P. D. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455–461

McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J. P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O'Dell, S., Patel, N., Shabzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G. Y., Diwanji, D., Georgiev, I., Kwon, Y. D., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z. Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L. X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., and Kwong, P. D. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343

Julien, J. P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., Caulfield, M. J., King, C. R., Marozsan, A. I., Klasse, P. J., Sanders, R. W., Moore, J. P., Wilson, I. A., and Ward, A. B. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U.S.A. 110, 4351–4356

Thali, M., Furman, C., Ho, D. D., Robinson, J., Tilley, S., Pinter, A., and Sodroski, J. (1992) Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66, 5635–5641

Chen, L., Kwon, Y. D., Zhou, T., Wu, X., O’Dell, S., Cavacini, L., Hessell, A. J., Pancera, M., Tang, M., Xu, L., Yang, Z. Y., Zhang, M. Y., Arthos, J., Burton, D. R., Dimitrov, D. S., Nabel, G. J., Posner, M. R., Sodroski, J., Wyatt, R., Mascola, J. R., and Kwong, P. D. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123–1127

Cavacini, L. A., Duval, M., Robinson, J., and Posner, M. R. (2002) Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 16, 2409–2417

Guenaga, J., de Val, N., Tran, K., Feng, Y., Satchwell, K., Ward, A. B., and Wyatt, R. T. (2015) Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog. 11, e1004570

Checkley, M. A., Luttgte, B. G., and Freed, E. O. (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410, 582–608

Sun, Z. Y., Oh, K. J., Kim, M., Yu, J., Brusic, V., Song, L., Qiao, Z., Wang, J. H., Wagner, G., and Reinherz, E. L. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28, 52–63

Bartsaghi, A., Merk, A., Borgia, M. J., Milne, J. L., and Subramaniam, S. (2013) Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat. Struct. Mol. Biol. 20, 1532–1537

Harris, A., Borgia, M. J., Shi, D., Bartsaghi, A., He, H., Pejchal, R., Kang, Y. K., Depetris, R., Marozsan, A. J., Sanders, R. W., Klasse, P. J., Milne, J. L., Wilson, I. A., Olson, W. C., Moore, J. P., and Subramaniam, S. (2011) Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U.S.A. 108, 11440–11445

DeLano, W. L. (2010) The PyMOL Molecular Graphics System, version 1.3r1, Schrodinger, LLC, New York